Tarlatamab-Dlle. Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg, 10 mg
Reference Brands: Imdelltra (USA), Imdylltra (EU/UK)
Category:
Oncology Cancer Care
Tarlatamab-dlle is a bispecific T-cell engager (BiTE) antibody that binds DLL3 on small cell lung cancer cells and CD3 on T cells, enabling targeted immune killing of tumor cells. It is approved for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. It has shown meaningful response rates and durable clinical benefit in resistant disease. The treatment is given by step-up intravenous infusion to reduce the risk of cytokine release syndrome. Patients are monitored closely for immune-related reactions and neurological side effects.
Tarlatamab-dlle. is available in Injection
and strengths such as 1 mg, 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tarlatamab-dlle. is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tarlatamab-dlle. can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing